MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral ...

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, ...

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for ...

BeiGene (NASDAQ:BGNE) announced Friday that the U.S. Food and Drug Administration (FDA) approved its cancer medicine Tevimbra ...

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in ...

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior ...

Tevimbra is also approved in the U.S. as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that doesn ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...